Desmopressin

Two changes to arginine vasopressin, deamination at position 1 and substitution of D-arginine at position 8, remove almost all V1a vasoconstrictor activity while keeping and prolonging V2 activity. V2 receptor binding on collecting-duct principal cells raises cyclic AMP and traffics aquaporin-2 water channels into the apical membrane, so water is reabsorbed and urine concentrates. Separately, V2 receptors on vascular endothelium trigger exocytosis of Weibel-Palade bodies, releasing von Willebrand factor and factor VIII within about 30 minutes, which is why the same molecule treats mild haemophilia A and type 1 von Willebrand disease. The clinically dangerous consequence of both routes is dilutional hyponatraemia if fluid intake is not restricted.

Targets: V2 vasopressin receptor, Aquaporin-2, Von Willebrand factor release, Factor VIII

• · Start low, at 0.05 mg twice daily, and titrate up on urine output and serum sodium.
• · 10 mcg is one spray of the 10 mcg per 0.1 mL nasal solution.
• · 27.7 mcg for women, 55.3 mcg for men. Contraindicated over age 65 with any hyponatraemia risk.
• · Dosed by weight at 0.3 mcg per kg. Tachyphylaxis develops after two or three doses as endothelial stores deplete.

Work out your exact syringe units →

• commonHyponatraemia— The defining risk. Can progress to confusion, seizures and death, especially in the elderly or with unrestricted fluid intake.
• commonHeadache— Often the first warning sign of falling sodium.
• commonNausea and abdominal cramps
• commonNasal congestion or epistaxis with nasal formulations
• uncommonFacial flushing and transient tachycardia— Mainly with rapid intravenous dosing for bleeding indications.
• rareThrombotic events— Reported with high-dose haemostatic use in patients with existing cardiovascular disease.

• Hyponatraemia or a history of it
• Moderate to severe renal impairment (eGFR below 50)
• Syndrome of inappropriate antidiuretic hormone secretion
• Uncontrolled heart failure or any condition requiring diuretic therapy
• Polydipsia, including habitual high fluid intake
• Type 2B von Willebrand disease

• redundantvasopressin — Desmopressin is the V2-selective, long-acting version of the same hormone.
• cautionoxytocin-obstetric — Both can cause water retention; combined use around delivery raises hyponatraemia risk.

• · Serum sodium at baseline, day 7, day 30 and periodically
• · Daily weight and urine output during titration
• · Fluid intake discipline, which matters more than any lab

Prescription drug worldwide; generic tablets and injection are inexpensive and widely available.

• DDAVP and Nocdurna FDA prescribing information (label)
• Mannucci 1997 Blood, review of desmopressin in bleeding disorders (review)
• FDA boxed warning on hyponatraemia for desmopressin nocturia products (label)

Two changes to a nine-residue hormone produce a completely different clinical drug. Deamination at position 1 removes the aminopeptidase substrate and roughly triples the duration. Swapping L-arginine for D-arginine at position 8 is the selectivity switch: V1a receptors on vascular smooth muscle need the L-configuration for productive binding and V2 receptors in the collecting duct do not, so the analogue keeps the antidiuretic arm and loses the pressor arm almost entirely. At the V2 receptor, Gs coupling raises cyclic AMP, protein kinase A phosphorylates aquaporin-2 at serine 256, and AQP2-bearing vesicles traffic to and fuse with the apical membrane of the principal cell. Water then follows the medullary osmotic gradient out of the tubule. Prolonged stimulation also upregulates AQP2 transcription, so the effect deepens over days rather than staying flat. The haemostatic effect runs through the same receptor in a different tissue: V2 receptors on vascular endothelium trigger exocytosis of Weibel-Palade bodies, dumping preformed von Willebrand factor multimers and the factor VIII bound to them into plasma within about 30 minutes, typically a three- to five-fold rise. That is a release mechanism, not a synthesis mechanism, which is exactly why tachyphylaxis appears after two or three doses: the stores are finite and take a day or more to refill. And the reason hyponatraemia is the dominant danger is structural rather than incidental. The drug removes the body's ability to excrete free water; if the patient keeps drinking to thirst, sodium falls, and the elderly brain tolerates that badly.

Fluid discipline is the whole game and it is where people fail. The drug removes your ability to excrete free water; drink normally, or drink to thirst after exercise or alcohol, and sodium falls. The classic disaster is a young person taking desmopressin for enuresis or nocturia who then goes out drinking. The second failure is bodybuilders and combat-sport competitors using desmopressin for water manipulation, which is both a doping violation and a well-documented route to seizures. The third is the tachyphylaxis trap in bleeding: a trial dose weeks before surgery works beautifully, three doses are given around the operation, and the third does nothing because the endothelial stores are empty. The fourth is nasal-to-oral switching errors, where the microgram numbers for the two routes differ by more than an order of magnitude and a straight substitution is a massive overdose. The fifth is missing the early symptoms: headache, nausea and mild confusion on desmopressin are hyponatraemia until proven otherwise, and they get blamed on a virus.

1. 50 mcgWeek 1, central diabetes insipidus, oral — 0.05 mg twice daily. Start deliberately low and let breakthrough polyuria happen rather than chasing complete suppression from day one.
2. 100 mcgWeeks 2-4 — 0.1 mg two or three times daily, adjusted on urine output and a day-7 sodium.
3. 400 mcgMaintenance — Typical maintenance is 0.1 to 0.4 mg per dose two or three times daily, total daily range 0.1 to 1.2 mg. Deliberately leaving a daily window of breakthrough diuresis is protective against hyponatraemia.
4. 27.7 mcgNocturia, sublingual, women — 27.7 mcg nightly. Fluid restriction from 1 hour before until 8 hours after is part of the dose, not an optional extra.
5. 55.3 mcgNocturia, sublingual, men — 55.3 mcg nightly. The sex difference is real: women develop hyponatraemia at lower doses. Sodium at day 7 and day 30 is mandatory.
6. —Haemostatic use, intravenous — 0.3 mcg per kilogram intravenously over 15 to 30 minutes, repeatable at 12 to 24 hours. Expect tachyphylaxis after two or three doses as endothelial stores deplete. Fluid restriction afterwards is essential; this is where the severe iatrogenic hyponatraemia cases come from.

• V2 vasopressin receptor on renal collecting duct — High and V2-selective by design. Numeric Ki not resolved this session.

  Gs coupling raises cyclic AMP, PKA phosphorylates aquaporin-2, water channels traffic to the apical membrane and free water is reabsorbed. Urine concentrates and volume falls for 6 to 12 hours.

• V2 receptor on vascular endothelium — High

  Exocytosis of Weibel-Palade bodies releasing von Willebrand factor and factor VIII within 30 to 60 minutes. Finite stores, hence tachyphylaxis after two or three doses.

• V1a vasopressin receptor — Very low; essentially abolished by the D-Arg8 substitution

  Minimal vasoconstriction. Residual activity explains occasional facial flushing and mild blood pressure change at high intravenous doses.

Antidiuresis begins within about an hour of an oral or intranasal dose and lasts 6 to 12 hours, which is what makes a single evening dose viable for nocturia. Factor VIII and von Willebrand factor peak 30 to 60 minutes after intravenous dosing with a haemostatic effect lasting around 6 to 12 hours. For central diabetes insipidus symptom control is immediate but finding the right dose and interval takes a week or two. Hyponatraemia, when it develops, typically appears in the first 7 to 30 days, which is exactly why the sodium checks sit where they do.

The dangerous stacks are all water-retention stacks. SSRIs, tricyclics, carbamazepine, chlorpropamide, NSAIDs and anything that itself causes SIADH multiply the hyponatraemia risk, and in elderly patients on an SSRI the combination is a genuinely common cause of hospital admission. Thiazides are a particular trap because they impair free water excretion in their own right. Oxytocin around delivery adds V2 activity from a second source. On the useful side, desmopressin combines rationally with tranexamic acid for bleeding indications, since one raises von Willebrand factor and the other prevents clot lysis, and that pairing is standard for dental and minor surgical procedures in mild von Willebrand disease. For nocturia, combining with an alpha-blocker for prostatic symptoms is common and sensible because they address different causes of the same complaint.

Against vasopressin: desmopressin is what you use when you want water retention without vasoconstriction, and vasopressin when you want the opposite. They are not interchangeable in any setting. Against terlipressin: terlipressin is the V1-selective mirror image, built for splanchnic constriction. For nocturia specifically, desmopressin is the only drug that addresses nocturnal polyuria itself rather than bladder capacity, but it is also the only one that can kill you through hyponatraemia, and over 65 the risk-benefit is genuinely marginal. For bleeding, desmopressin carries no infectious risk and is cheap compared with factor concentrate, but it only works in mild haemophilia A and responsive type 1 von Willebrand disease, is useless in severe haemophilia, and is contraindicated in type 2B where it worsens thrombocytopenia.

$15–$120/month. Unverified estimate. Generic desmopressin tablets are genuinely cheap in the US and most other markets; the branded sublingual and nasal nocturia products are substantially more expensive. Not sourced in this session.

• ?Oral, sublingual and intranasal bioavailability percentages are left null. The commonly quoted figures are a small fraction of one percent orally and low single digits intranasally, but I could not resolve a label this session, and these are exactly the numbers that get repeated wrongly.
• ?Volume of distribution and plasma protein binding were not stated in the label section I resolved.
• ?The tmax of 1 hour reflects onset of antidiuresis after oral or intranasal dosing rather than a measured plasma tmax.
• ?No numeric V2 receptor binding affinity was resolved this session.
• ?Cost figures are unverified estimates.

• Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years Mannucci PM, Blood, 1997 · PMID 9326215

  The definitive review of the haemostatic use, written by the person who developed it. Blood 1997;90(7):2515-21.

• Desmopressin acetate injection - FDA prescribing information DailyMed

  Source of the 2.8 hour terminal half-life, its extension to 8.7 hours in severe renal impairment, the 52 percent unchanged urinary recovery, the absence of CYP450 metabolism, and the chemical name.